| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 0 | 39,610 | 40,020 | 33,870 | 35,100 |
| Sales Growth | -100.00% | -1.02% | +18.16% | -3.50% | -4.59% |
| Net Income | -7,810 | 10,990 | -16,890 | -8,500 | -11,960 |
| Net Income Growth | -171.06% | +165.07% | -98.71% | +28.93% | -113.19% |
Janone Inc (JAN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.23 +0.09 (+4.21%) 07/12/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.23 unch (unch) -
for Fri, Jul 12th, 2024
JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.